STOCK TITAN
  1. Home
  2. News
  3. ECOR

ElectroCore Inc - ECOR STOCK NEWS

Welcome to our dedicated news page for ElectroCore (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on ElectroCore.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ElectroCore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ElectroCore's position in the market.

News
electroCore Announces the Launch of Truvaga Plus® for General Wellness
Rhea-AI Summary
electroCore, Inc. (ECOR) launches Truvaga Plus, a mobile app-enabled wellness product for stress management and overall wellbeing. The product offers features like mobile app connectivity, unlimited sessions, rechargeable design, and compact size. CEO Dan Goldberger highlights the innovative technology and benefits of Truvaga Plus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News
electroCore Expands Intellectual Property Portfolio
Rhea-AI Summary
electroCore, Inc. (ECOR) has been granted two new U.S. patents related to its non-invasive vagus nerve stimulation (nVNS) technology by the United States Patent and Trademark Office (USPTO). The patents focus on stimulating nerves using a mobile device and treating central nervous system disorders like PTSD, fibromyalgia, anxiety, and TBI with electrical impulses. This development showcases the company's commitment to innovation and advancing bioelectronic medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
-
News
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
electroCore, Inc. (ECOR) reported a significant increase in net sales for the full year 2023, reaching $16.0 million, an 87% growth over 2022. The company highlighted revenue growth across major channels, including prescription gammaCore devices and nonprescription products. Despite a rise in gross profit and a decrease in research and development expenses, the company faced increased operating expenses, resulting in a GAAP net loss of $18.8 million for 2023. Adjusted EBITDA net loss improved in Q4 2023 compared to Q4 2022. The company's cash position decreased from $18.0 million in 2022 to $10.6 million in 2023, despite raising $7.5 million through a direct offering in July 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
earnings
News
electroCore to Participate in Upcoming Investor Conferences
Rhea-AI Summary
electroCore, Inc. (ECOR) announces participation in upcoming investor conferences. Chief Strategy Officer Joshua Lev and CEO Dan Goldberger to attend Roth and Needham conferences for investor meetings and company presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
conferences
-
News
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
Rhea-AI Summary
electroCore, Inc. (ECOR) to report Q4 and year-end 2023 financial results on March 13, 2024. Conference call scheduled to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
earnings
-
News
electroCore Expands Intellectual Property Portfolio
Rhea-AI Summary
ElectroCore, Inc. (Nasdaq: ECOR) has announced the issuance of a patent by the United States Patent and Trademark Office related to treating disorders associated with viruses in the Coronaviridae family (COVID) using electrical impulses transcutaneously to the vagus nerve. The patent, U.S. Patent No. 11,894,148, covers systems and methods for treating patients with diseases associated with viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
News
electroCore Expands Intellectual Property Portfolio
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announced the issuance of a patent by the United States Patent and Trademark Office related to treating post-traumatic stress disorder (PTSD) using vagal nerve stimulation. The patent, U.S. Patent No. 11,865,329, covers methods for treating PTSD symptoms by applying electrical impulses to the vagus nerve for a specific duration and pulse pattern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
News
electroCore Expands Intellectual Property Portfolio
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) has been granted two new U.S. patents related to its non-invasive vagus nerve stimulation (nVNS) technology. The patents, US Patent No. 11,850,056 and US Patent No. 11,854,695, were issued on December 26, 2023, and focus on remote therapy and patient monitoring, as well as medical devices for treating medical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
-
News
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,839,764 by the United States Patent and Trademark Office. The patent is related to a system for stimulating a nerve target in the head or neck of a patient for the treatment of various disorders, including primary headache. It involves a downloadable software program on a mobile device that controls the electrical impulses delivered by a stimulator to target nerves in the head or neck. This strengthens the company's intellectual property portfolio and positions them for the development of next-generation application-enabled products and devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
News
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
Rhea-AI Summary
electroCore, Inc. (Nasdaq: ECOR) announces its Chief Medical Officer, Dr. Peter Staats, will host an analyst day on November 21, 2023, to discuss the potential of Vagus Nerve Stimulation with gammaCore™. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology platform embodied in its gammaCore product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
conferences
Stock ECOR logo
ElectroCore Inc

Nasdaq:ECOR

ECOR Rankings

#4926 Ranked by Market Cap
#411 Ranked by Stock Gains
N/A Ranked by Dividends

ECOR Stock Data

34.46M
4.17M
18.51%
16.59%
0.17%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Rockaway

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.